Zachary Bessette

Zachary Bessette

Articles by Zachary Bessette

Zachary BessettenccRCC | February 21, 2024
A new study on the prognostic value of perinephric fat, renal sinus fat, and renal vein invasion in patients with pT3a RCC.
Read More
Zachary BessetteAdvanced Imaging | February 15, 2024
Initial data from the COBRA trial confirm that 64Cu-SAR-bisPSMA is safe and “highly” effective in detecting BCR PC.
Zachary BessetteASCO GU Symposium 2024 | January 27, 2024
After 57 months of follow-up, adjuvant pembro demonstrates improvement in OS in patients with ccRCC at risk of recurrence.
Zachary BessetteASCO GU Symposium 2024 | February 5, 2024
Improved outcomes in patients with previously untreated la/mUC after EV/pembro, even in poor prognosis patient subgroups.
Zachary BessetteASCO GU Symposium 2024 | February 1, 2024
Adjuvant pembrolizumab demonstrates improvement in DFS for patients with high-risk MIUC after radical surgery.
Zachary BessetteASCO GU Symposium 2024 | January 30, 2024
A retrospective study of patients with accRCC offers understandings of the role of tivozanib in the current RCC landscape.
Zachary BessetteASCO GU Symposium 2024 | January 25, 2024
uMRD enables quantitative assessment of molecular response to nadofaragene firadenovec for BCG-unresponsive NMIBC.
Zachary BessetteASCO GU Symposium 2024 | January 25, 2024
Researchers performed an exploratory biomarker analysis using different definitions of ctDNA response in the ABACUS trial.
Zachary BessetteASCO GU Symposium 2024 | January 25, 2024
Prolonged avelumab first-line maintenance treatment is associated with stable PROs for those with aUC.
Zachary BessetteASCO GU Symposium 2024 | February 1, 2024
An early-stage trial highlights the antitumor activity from erdafitinib plus EV for mUC with FGFR2/3 genetic alterations.
Zachary BessetteASCO GU Symposium 2024 | January 24, 2024
Cabozantinib plus atezolizumab improves rPFS versus second NHT in patients who had progressed on a prior NHT and have mCRPC.
Zachary BessetteAdvanced Urothelial Carcinoma | February 16, 2024
The FDA has approved erdafitinib for adult patients with mUC and susceptible FGFR3 genetic alterations.
Zachary BessetteRLT | January 19, 2024
Dr. Oliver Sartor presented his high-level “provocateur” thoughts on the optimal time to give PSMA RLT.
Zachary BessetteAdvanced Imaging | January 19, 2024
At the 2024 PSMA Conference, Dr. Wolfgang Fendler gave an update on the capabilities of PSMA PET in advanced prostate cancer.
Zachary BessetteAdvanced Imaging | December 22, 2023
The first patient has been dosed in the CLARIFY trial, an investigation into 64Cu-SAR-bisPSMA in prostate cancer.
Zachary BessetteAdvanced Urothelial Carcinoma | December 18, 2023
Dr. Thomas Powles is the only physician and cancer researcher in the world to be featured on Nature’s 10.
Zachary BessetteRenal Cell Carcinoma | December 13, 2023
The first US patient has been dosed with TLX250-CDx, a noninvasive investigational PET imaging agent for ccRCC.
Zachary BessetteCRPC | December 6, 2023
ASCO has provided a rapid update on its guideline recommendations for 177Lutetium-PSMA-617 in mCRPC.
Zachary BessetteAdvanced Urothelial Carcinoma | December 5, 2023
A recent combined analysis of 2 phase 2 studies indicates that disitamab vedotin has a promising efficacy and safety profile.
Zachary BessetteAdvanced Urothelial Carcinoma | December 5, 2023
The FDA is granting a priority review for EV/pembro as well as nivo/chemo for the treatment of patients with la/mUC.